Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 21.9% during trading on Tuesday . The stock traded as high as C$0.20 and last traded at C$0.20. 262,425 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 496,726 shares. The stock had previously closed at C$0.16.
Hemostemix Price Performance
The business’s 50-day moving average price is C$0.20 and its 200 day moving average price is C$0.12. The company has a market capitalization of C$27.69 million, a P/E ratio of -5.54 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What is diluted earnings per share (Diluted EPS)?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
